Tradestie Institutional Equity Comparison Engine

CBIO vs CAMP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CBIO Overall Edge

CBIO Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Momentum & Technical, Options & Structure while CAMP counters with relative strength in Growth & Margin. Fundamentally, CBIO trades at N/M Forward P/E with -1228.4% operating margin (+0.0% YoY revenue) versus CAMP at N/M Forward P/E and -991.8% operating margin (+138.9% YoY). In options structure, CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CAMP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CBIO N/M vs CAMP N/M Fwd P/E
Growth & Margin Winner CAMP
Op Margin -1228.4% vs -991.8% ยท YoY +0.0% vs +138.9%
Momentum & Technical Winner CBIO
1Y +0.3% vs -2.4% ยท 52W Pos 23% vs 23%
Options & Structure Winner CBIO
BREAKDOWN (10th %ile IV) vs UNCLASSIFIED (N/A IV)
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.05
-3.3% 1D
Market Cap $591.3M
1M Return +5.62%
1Y Return +0.27%
Forward P/E N/M
Unified AI Score
42.4 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 65.0 Mom 50.0
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
1M Return +27.39%
1Y Return -2.44%
Forward P/E N/M
Unified AI Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CBIO +0.27% CAMP -2.44% Spread: +2.71 pp (CBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CBIO Revenue CAMP Revenue CBIO Op. Margin CAMP Op. Margin Margin Edge
FY2015 $20M N/A -63.7% N/A CBIO
FY2016 $0M N/A -172505.3% N/A CBIO
FY2020 $10M N/A -506.8% N/A CBIO
FY2021 $0M N/A -5470.7% N/A CBIO
FY2022 $0M N/A -63204.4% N/A CBIO
FY2023 $0M $0M -392752.9% -14822.6% CAMP
FY2024 N/A $0M N/A -8142.3% CAMP
FY2025 $10M $0M -1407.5% -1502.4% CBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CBIO (2) vs CAMP (4)
Institutional Metric CBIO CAMP Criterion Row Winner
Market Capitalization Scale $591.3M $238.5M Larger Scale CBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +138.9% Higher Growth CAMP
Operating Margin (TTM) Profitability -1228.4% -991.8% Higher Margin CAMP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -160.8% -146.1% Higher ROE CAMP
52-Week Range Position Momentum 23% ($9โ€“$27) 23% ($3โ€“$8) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.37ฮฒ ยท 58% Vol 1.35ฮฒ ยท 94% Vol Lower Realized Risk CBIO
Unified Institutional Score Composite Signal 42.4 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite CAMP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CBIO vs CAMP Buy Guide
CBIO BREAKDOWN
145d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CAMP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CBIO nor CAMP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.